{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,20]],"date-time":"2026-05-20T08:31:31Z","timestamp":1779265891151,"version":"3.51.4"},"reference-count":43,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100008530","name":"European Regional Development Fund","doi-asserted-by":"publisher","award":["463001015"],"award-info":[{"award-number":["463001015"]}],"id":[{"id":"10.13039\/501100008530","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100007601","name":"Horizon 2020","doi-asserted-by":"publisher","award":["825575"],"award-info":[{"award-number":["825575"]}],"id":[{"id":"10.13039\/501100007601","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004587","name":"Instituto de Salud Carlos III","doi-asserted-by":"publisher","award":["PI21\/00165"],"award-info":[{"award-number":["PI21\/00165"]}],"id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004587","name":"Instituto de Salud Carlos III","doi-asserted-by":"publisher","award":["PI18\/00067"],"award-info":[{"award-number":["PI18\/00067"]}],"id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Revue Neurologique"],"published-print":{"date-parts":[[2024,11]]},"DOI":"10.1016\/j.neurol.2024.07.004","type":"journal-article","created":{"date-parts":[[2024,9,19]],"date-time":"2024-09-19T14:06:13Z","timestamp":1726754773000},"page":"940-949","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":11,"title":["Clinical presentations and antibody mechanisms in anti-IgLON5 disease"],"prefix":"10.1016","volume":"180","author":[{"given":"C.","family":"Gaig","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8556-6166","authenticated-orcid":false,"given":"L.","family":"Sabater","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.neurol.2024.07.004_bib0220","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1016\/S1474-4422(14)70051-1","article-title":"A novel non-rapid-eye movement and rapid-eye-movement parasomnia with sleep breathing disorder associated with antibodies to IgLON5: a case series, characterisation of the antigen, and post-mortem study","volume":"13","author":"Sabater","year":"2014","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.neurol.2024.07.004_bib0225","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1056\/NEJMra1708712","article-title":"Antibody-mediated encephalitis","volume":"378","author":"Dalmau","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.neurol.2024.07.004_bib0230","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1007\/s00401-016-1591-8","article-title":"Neuropathological criteria of anti-IgLON5-related tauopathy","volume":"132","author":"Gelpi","year":"2016","journal-title":"Acta Neuropathol"},{"key":"10.1016\/j.neurol.2024.07.004_bib0235","doi-asserted-by":"crossref","first-page":"zsz133","DOI":"10.1093\/sleep\/zsz133","article-title":"Characterization of the sleep disorder of anti-IgLON5 disease","volume":"42","author":"Gaig","year":"2019","journal-title":"Sleep"},{"key":"10.1016\/j.neurol.2024.07.004_bib0240","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1007\/s11910-018-0848-0","article-title":"The sleep disorder in anti-lgLON5 disease","volume":"18","author":"Gaig","year":"2018","journal-title":"Curr Neurol Neurosci Rep"},{"key":"10.1016\/j.neurol.2024.07.004_bib0245","doi-asserted-by":"crossref","first-page":"1736","DOI":"10.1212\/WNL.0000000000003887","article-title":"Clinical manifestations of the anti-IgLON5 disease","volume":"88","author":"Gaig","year":"2017","journal-title":"Neurology"},{"key":"10.1016\/j.neurol.2024.07.004_bib0250","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1093\/brain\/awac090","article-title":"Clinical, serological and genetic predictors of response to immunotherapy in anti-IgLON5 disease","volume":"146","author":"Gr\u00fcter","year":"2023","journal-title":"Brain"},{"issue":"3","key":"10.1016\/j.neurol.2024.07.004_bib0255","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1097\/WCO.0000000000001271","article-title":"New knowledge on anti-IgLON5 disease","volume":"37","author":"Gaig","year":"2024","journal-title":"Curr Opin Neurol"},{"key":"10.1016\/j.neurol.2024.07.004_bib0260","doi-asserted-by":"crossref","first-page":"e385","DOI":"10.1212\/NXI.0000000000000385","article-title":"IgLON5 antibody","volume":"4","author":"Honorat","year":"2017","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"10.1016\/j.neurol.2024.07.004_bib0265","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1212\/NXI.0000000000000302","article-title":"Isolated dysphagia as initial sign of anti-IgLON5 syndrome","volume":"4","author":"Schr\u00f6der","year":"2017","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"10.1016\/j.neurol.2024.07.004_bib0270","doi-asserted-by":"crossref","first-page":"1590","DOI":"10.1016\/S0140-6736(15)60445-7","article-title":"IgLON5 autoimmunity and abnormal behaviours during sleep","volume":"385","author":"H\u00f6gl","year":"2015","journal-title":"Lancet"},{"key":"10.1016\/j.neurol.2024.07.004_bib0275","doi-asserted-by":"crossref","first-page":"e962","DOI":"10.1212\/NXI.0000000000000962","article-title":"Anti-IgLON5 disease: a new bulbar-onset motor neuron mimic syndrome","volume":"8","author":"Werner","year":"2021","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"10.1016\/j.neurol.2024.07.004_bib0280","doi-asserted-by":"crossref","first-page":"e1367","DOI":"10.1212\/WNL.0000000000012639","article-title":"Frequency and characterization of movement disorders in anti-IgLON5 disease","volume":"97","author":"Gaig","year":"2021","journal-title":"Neurology"},{"key":"10.1016\/j.neurol.2024.07.004_bib0285","doi-asserted-by":"crossref","first-page":"106992","DOI":"10.1016\/j.parkreldis.2024.106992","article-title":"Anti-IgLON5 disease as a differential diagnosis of multiple system atrophy","volume":"124","author":"Ono","year":"2024","journal-title":"Parkinsonism Relat Disord"},{"key":"10.1016\/j.neurol.2024.07.004_bib0290","doi-asserted-by":"crossref","first-page":"2187","DOI":"10.2169\/internalmedicine.2865-23","article-title":"A case of anti-IgLON5 disease showing an improvement in dysautonomia, including vocal cord palsy, via combined immunotherapy","volume":"63","author":"Sato","year":"2024","journal-title":"Intern Med"},{"key":"10.1016\/j.neurol.2024.07.004_bib0295","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1212\/NXI.0000000000000136","article-title":"Sleep disorder, chorea, and dementia associated with IgLON5 antibodies","volume":"2","author":"Simabukuro","year":"2015","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"10.1016\/j.neurol.2024.07.004_bib0300","doi-asserted-by":"crossref","first-page":"S83","DOI":"10.1002\/mdc3.13061","article-title":"Chorea in IgLON5-mediated autoimmune encephalitis","volume":"7","author":"Aslam","year":"2020","journal-title":"Mov Disord Clin Pract"},{"key":"10.1016\/j.neurol.2024.07.004_bib0305","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1002\/mdc3.13614","article-title":"Anti-IgLON5 disease with isolated hemichorea: a case report and review of the literature","volume":"10","author":"Grossauer","year":"2023","journal-title":"Mov Disord Clin Pract"},{"key":"10.1016\/j.neurol.2024.07.004_bib0310","doi-asserted-by":"crossref","first-page":"753856","DOI":"10.3389\/fimmu.2021.753856","article-title":"Ocular motor abnormalities in anti-IgLON5 disease","volume":"12","author":"Macher","year":"2021","journal-title":"Front Immunol"},{"key":"10.1016\/j.neurol.2024.07.004_bib0315","doi-asserted-by":"crossref","first-page":"849","DOI":"10.3390\/diagnostics12040849","article-title":"Neuroimaging findings in a patient with anti-IgLON5 disease: cerebrospinal fluid dynamics abnormalities","volume":"12","author":"Urso","year":"2022","journal-title":"Diagnostics"},{"key":"10.1016\/j.neurol.2024.07.004_bib0320","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.3389\/fneur.2019.01056","article-title":"Anti-IgLON5 disease: a case with 11-year clinical course and review of the literature","volume":"10","author":"Brilot","year":"2019","journal-title":"Front Neurol"},{"key":"10.1016\/j.neurol.2024.07.004_bib0325","doi-asserted-by":"crossref","first-page":"632497","DOI":"10.3389\/fneur.2021.632497","article-title":"Case report: neuropsychological findings in IgLON5 antibody disorder","volume":"12","author":"Lynch","year":"2021","journal-title":"Front Neurol"},{"key":"10.1016\/j.neurol.2024.07.004_bib0330","doi-asserted-by":"crossref","first-page":"e1039","DOI":"10.1212\/NXI.0000000000001039","article-title":"Autoimmune encephalitis resembling dementia syndromes from the department of neurology","volume":"8","author":"Bastiaansen","year":"2021","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"10.1016\/j.neurol.2024.07.004_bib0335","doi-asserted-by":"crossref","first-page":"6139","DOI":"10.1007\/s00415-022-11262-0","article-title":"Motor-neuron-disease-like phenotype associated with IgLON5 disease","volume":"269","author":"Sista","year":"2022","journal-title":"J Neurol"},{"key":"10.1016\/j.neurol.2024.07.004_bib0340","doi-asserted-by":"crossref","first-page":"1305","DOI":"10.1111\/cns.13038","article-title":"Motor neuron disease-like phenotype associated with anti-IgLON5 disease","volume":"24","author":"Tao","year":"2018","journal-title":"CNS Neurosci Ther"},{"key":"10.1016\/j.neurol.2024.07.004_bib0345","doi-asserted-by":"crossref","first-page":"800298","DOI":"10.3389\/fneur.2022.800298","article-title":"Epileptic seizures and right-sided hippocampal swelling as presenting symptoms of anti-IgLON5 disease: a case report and systematic review of the literature","volume":"13","author":"Fu","year":"2022","journal-title":"Front Neurol"},{"key":"10.1016\/j.neurol.2024.07.004_bib0350","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1212\/NXI.0000000000000485","article-title":"Subacute encephalitis with recovery in IgLON5 autoimmunity","volume":"5","author":"Ramanan","year":"2018","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"10.1016\/j.neurol.2024.07.004_bib0355","doi-asserted-by":"crossref","first-page":"e605","DOI":"10.1212\/NXI.0000000000000605","article-title":"HLA and microtubule-associated protein tau H1 haplotype associations in anti-IgLON5 disease","volume":"6","author":"Gaig","year":"2019","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"10.1016\/j.neurol.2024.07.004_bib0360","doi-asserted-by":"crossref","first-page":"2579","DOI":"10.1093\/brain\/awae048","article-title":"HLA-DQB1*05 subtypes and not DRB1*10:01 mediates risk in anti-IgLON5 disease","volume":"147","author":"Yogeshwar","year":"2024","journal-title":"Brain"},{"key":"10.1016\/j.neurol.2024.07.004_bib0365","doi-asserted-by":"crossref","first-page":"e2325","DOI":"10.1212\/WNL.0000000000207870","article-title":"In vivo measurement of tau depositions in anti-IgLON5 disease using [18F]PI-2620 PET","volume":"101","author":"Theis","year":"2023","journal-title":"Neurology"},{"key":"10.1016\/j.neurol.2024.07.004_bib0370","doi-asserted-by":"crossref","first-page":"e208101","DOI":"10.1212\/WNL.0000000000208101","article-title":"Development of a composite score for the clinical assessment of anti-IgLON5 disease","volume":"102","author":"Gaig","year":"2024","journal-title":"Neurology"},{"key":"10.1016\/j.neurol.2024.07.004_bib0375","doi-asserted-by":"crossref","first-page":"e651","DOI":"10.1212\/NXI.0000000000000651","article-title":"Anti-IGLON5 disease: a new case without neuropathologic evidence of brainstem tauopathy","volume":"7","author":"Erro","year":"2020","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"10.1016\/j.neurol.2024.07.004_bib0380","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1007\/s00401-023-02625-6","article-title":"Analysis of inflammatory markers and tau deposits in an autopsy series of nine patients with anti-IgLON5 disease","volume":"146","author":"Berger-Sieczkowski","year":"2023","journal-title":"Acta Neuropathol"},{"key":"10.1016\/j.neurol.2024.07.004_bib0385","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1186\/s12974-016-0689-1","article-title":"Cellular investigations with human antibodies associated with the anti-IgLON5 syndrome","volume":"13","author":"Sabater","year":"2016","journal-title":"J Neuroinflamm"},{"key":"10.1016\/j.neurol.2024.07.004_bib0390","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1002\/ana.25857","article-title":"Effects of IgLON5 antibodies on neuronal cytoskeleton: a link between autoimmunity and neurodegeneration","volume":"88","author":"Landa","year":"2020","journal-title":"Ann Neurol"},{"key":"10.1016\/j.neurol.2024.07.004_bib0395","doi-asserted-by":"crossref","first-page":"837","DOI":"10.3390\/cells10040837","article-title":"Neurodegeneration induced by anti-iglon5 antibodies studied in induced pluripotent stem cell-derived human neurons","volume":"10","author":"Ryding","year":"2021","journal-title":"Cells"},{"key":"10.1016\/j.neurol.2024.07.004_bib0400","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1016\/j.jaut.2016.11.005","article-title":"IgG4 autoantibodies against muscle-specific kinase undergo Fab-arm exchange in myasthenia gravis patients","volume":"77","author":"Koneczny","year":"2017","journal-title":"J Autoimmun"},{"key":"10.1016\/j.neurol.2024.07.004_bib0405","doi-asserted-by":"crossref","first-page":"1346671","DOI":"10.3389\/fimmu.2024.1346671","article-title":"Exploring the depths of IgG4: insights into autoimmunity and novel treatments","volume":"15","author":"\u00dcnl\u00fc","year":"2024","journal-title":"Front Immunol"},{"key":"10.1016\/j.neurol.2024.07.004_bib0410","doi-asserted-by":"crossref","first-page":"1151574","DOI":"10.3389\/fimmu.2023.1151574","article-title":"Patients\u2019 IgLON5 autoantibodies interfere with IgLON5-protein interactions","volume":"14","author":"Landa","year":"2023","journal-title":"Front Immunol"},{"key":"10.1016\/j.neurol.2024.07.004_bib0415","doi-asserted-by":"crossref","first-page":"1024","DOI":"10.3390\/cells11061024","article-title":"Pilot study of the effects of chronic intracerebroventricular infusion of human anti-IgLON5 disease antibodies in mice","volume":"11","author":"Alvente","year":"2022","journal-title":"Cells"},{"key":"10.1016\/j.neurol.2024.07.004_bib0420","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12974-022-02520-z","article-title":"Anti-IgLON5 antibodies cause progressive behavioral and neuropathological changes in mice","volume":"19","author":"Ni","year":"2022","journal-title":"J Neuroinflamm"},{"key":"10.1016\/j.neurol.2024.07.004_bib0425","doi-asserted-by":"crossref","first-page":"2483","DOI":"10.3390\/biomedicines11092483","article-title":"Purified serum IgG from a patient with anti-IgLON5 antibody cause long-term movement disorders with impaired dopaminergic pathways in mice","volume":"11","author":"Gao","year":"2023","journal-title":"Biomedicines"},{"key":"10.1016\/j.neurol.2024.07.004_bib0430","doi-asserted-by":"crossref","first-page":"e200234","DOI":"10.1212\/NXI.0000000000200234","article-title":"Phenotypic insights into anti-IgLON5 disease in IgLON5-deficient mice","volume":"11","author":"Lee","year":"2024","journal-title":"Neurol Neuroimmunol Neuroinflamm"}],"container-title":["Revue Neurologique"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S003537872400585X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S003537872400585X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T05:49:30Z","timestamp":1777441770000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S003537872400585X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11]]},"references-count":43,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2024,11]]}},"alternative-id":["S003537872400585X"],"URL":"https:\/\/doi.org\/10.1016\/j.neurol.2024.07.004","relation":{},"ISSN":["0035-3787"],"issn-type":[{"value":"0035-3787","type":"print"}],"subject":[],"published":{"date-parts":[[2024,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Clinical presentations and antibody mechanisms in anti-IgLON5 disease","name":"articletitle","label":"Article Title"},{"value":"Revue Neurologique","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.neurol.2024.07.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier Masson SAS. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}